Mitochondrial Apoptotic Priming Is Associated with Clinical Response to the Bcl-2 Antagonist ABT-199 in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Davids, Matthew S. [1 ]
Deng, Jing [1 ]
Ryan, Jeremy [1 ]
Fernandes, Stacey M. [1 ]
Brown, Jennifer R. [1 ]
Letai, Anthony G. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
    Shundong Cang
    Chaitanya Iragavarapu
    John Savooji
    Yongping Song
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [2] The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia
    Itchaki, Gilad
    Brown, Jennifer R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (05) : 270 - 287
  • [3] ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
    Cang, Shundong
    Iragavarapu, Chaitanya
    Savooji, John
    Song, Yongping
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [4] ABT-199: Taking Dead Aim at BCL-2
    Davids, Matthew S.
    Letai, Anthony
    CANCER CELL, 2013, 23 (02) : 139 - 141
  • [5] SELECTIVE INHIBITION OF BCL-2 IS ACTIVE AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FIRST CLINICAL EXPERIENCE WITH THE BH3-MIMETIC ABT-199
    Roberts, A.
    Davids, M.
    Mahadevan, D.
    Anderson, M.
    Kipps, T.
    Pagel, J.
    Kahl, B.
    Wierda, W.
    Darden, D.
    Nolan, C.
    Xiong, H.
    Huang, D.
    Chyla, B.
    Busman, T.
    Cerri, E.
    Enschede, S.
    Humerickhouse, R.
    Seymour, J.
    HAEMATOLOGICA, 2012, 97 : 219 - 220
  • [6] Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
    Patel, V. M.
    Balakrishnan, K.
    Douglas, M.
    Tibbitts, T.
    Xu, E. Y.
    Kutok, J. L.
    Ayers, M.
    Sarkar, A.
    Guerrieri, R.
    Wierda, W. G.
    O'Brien, S.
    Jain, N.
    Stern, H. M.
    Gandhi, V.
    LEUKEMIA, 2017, 31 (09) : 1872 - 1881
  • [7] MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells
    Wang, Qing
    Wan, Jiangbo
    Zhang, Wenhao
    Hao, Siguo
    LEUKEMIA & LYMPHOMA, 2019, 60 (09) : 2170 - 2180
  • [8] Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
    V M Patel
    K Balakrishnan
    M Douglas
    T Tibbitts
    E Y Xu
    J L Kutok
    M Ayers
    A Sarkar
    R Guerrieri
    W G Wierda
    S O'Brien
    N Jain
    H M Stern
    V Gandhi
    Leukemia, 2017, 31 : 1872 - 1881
  • [9] Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer
    Jing Deng
    Anthony Letai
    Breast Cancer Research, 15
  • [10] Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer
    Deng, Jing
    Letai, Anthony
    BREAST CANCER RESEARCH, 2013, 15 (05)
12345